{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.4","upperLimit":"27.8","value":"19.81"},{"groupId":"OG001","lowerLimit":"30.1","upperLimit":"30.1","value":"30.1"},{"comment":"Not calculated for total population in Phase 1 part because calculated for each cancer type (i.e., NSCLC and MPM separately)","groupId":"OG002","lowerLimit":"19.4","upperLimit":"30.1","value":"NA"},{"groupId":"OG003","lowerLimit":"3.0","upperLimit":"28.6","value":"12.14"},{"groupId":"OG004","lowerLimit":"3.0","upperLimit":"30.1","value":"12.75"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"25"}],"units":"Participants"}],"description":"OS was defined as the time from BBI608 administration to death from any cause. Participants alive at final observation or lost to follow-up were censored at their last contact (i.e., visit or telephone) date.","dispersionType":"Full Range","groups":[{"description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days.","id":"OG000","title":"NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)"},{"description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days.","id":"OG001","title":"MPM: BBI608 + Pem +CDDP (Phase 1 Part)"},{"description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days.","id":"OG002","title":"MPM or NSCLC: BBI608 + Pem + CDDP (Phase 1 Part)"},{"description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days.","id":"OG003","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part)"},{"description":"Participants orally received BBI608 (480 mg) twice daily plus intravenously received Pem (500 mg/m2) and CDDP (75 mg/m2) on Day 3 in only Cycles 1 and on Days 1 in Cycles 2 and subsequent cycles.\n\nPremeditation with folic acid and vitamin B12 was given to reduce occurrence of serious adverse drug reactions, with reference to the package insert for Pem. Each cycle was defined as 21 days.","id":"OG004","title":"MPM: BBI608 + Pem + CDDP (Phase 2 Part Including 1 Participant With MPM in Phase 1 Part)"}],"paramType":"MEDIAN","populationDescription":"modified ITT population. Efficacy was analyzed using the efficacy analysis population (i.e., modified ITT population; mITT), separately for Phase 1 part (n=4), Phase 2 part (n=24) and Phase 2 part including 1 participant with MPM in Phase 1 part (n=25).","reportingStatus":"POSTED","timeFrame":"From BBI608 administration to death from any cause, up to 31 months","title":"Overall Survival(OS)","type":"SECONDARY","unitOfMeasure":"month"}